|
| First author (year) | No of patient | Criteria of delayed hyponatremia | Delayed hyponatremia, N (%) | Symptomatic delayed hyponatremia, N (%) | As cause for unplanned readmission within 30 days |
|
| Rajaratnam (2020) | 222 | Serum sodium <135 mmol/L on or after POD 3 | 58 (26%) | 11 (5%) | N/A |
| Schur (2020) | 84 | Serum sodium <135 mmol/L, on or after POD 5 | 5 (6%) | N/A | N/A |
| Patel (2019) | 367 | Serum sodium <135 mmol/L with associated symptoms | 55 (15%) | 55 (15%) | 20/33 |
| Younus (2019) | 584 | Serum sodium <135 mmol/L under routine screening on POD 6, with associated symptoms | 16 (2.7%) | 16 (2.7%) | 16/27 |
| Yoon (2019) | 234 | Serum sodium <135 mmol/L on or after POD 3 | 53 (22.6%) | 5 (2.1%) | N/A |
| Tomita (2019) | 107 | Serum sodium <135 mmol/L on or after POD 3 | 25 (23.4%) | N/A | N/A |
| Agam (2018) | 1153 | Serum sodium <135 mmol/L with associated symptoms | 48 (4.2%) | 48 (4.2%) | N/A |
| Bohl (2018) | 172 | Serum sodium <135 mmol/L under screening | 29 (15%) | 11 (6%) | N/A |
| Burke (2018) | 788 | Serum sodium <135 mmol/L with associated symptoms | 20 (2.5%) | 20 (2.5%) | N/A |
| Deaver (2018) | 287 | Serum sodium <135 mmol/L with associated symptoms | 13 (4.5%) | 13 (4.5%) | 13/25 |
| Hollon (2018) | 400 | Serum sodium <135 mmol/L on or after POD 3 | 54 (14.3%) | N/A | N/A |
| Krogh (2018) | 314 | Serum sodium <130 mmol/L on POD 6–8 | 26 (8.3%) | 14 (4.46%) | 14/56 |
| Bohl (2016) | 303 | Serum sodium <135 mmol/L with associated symptoms | 15 (4.95%) | 15 (4.95%) | 15/27 |
| Barber (2014) | 344 | Serum sodium <135 mmol/L on or after POD 3 | 35 (10.2%) | N/A | N/A |
| Yamada (2014) | 90 | Serum sodium <135 mmol/L on or after POD 3 | 9 (10%) | N/A | N/A |
| Hussain (2013) | 339 | Serum sodium <130 mmol/L on POD 6–13 | 50 (15%) | 22 (6.4%) | N/A |
| Mamelak (2013) | 300 | Serum sodium <133 mmol/L on or after POD 3 | 37 (12.33%) | 8 (2.67%) | 8/38 |
| Chen (2011) | 385 | Serum sodium <135 mmol/L on or after POD 3 | 85 (22.1%) | N/A | N/A |
| Kinoshita (2011) | 88 | Serum sodium <135 mmol/L with associated symptoms | 27 (30.7%) | 9 (10.2%) | N/A |
| Zada (2010) | 169 | Serum sodium <135 mmol/L on or after POD 3 | 4 (2%) | N/A | N/A |
| Lee (2008) | 94 | Serum sodium <135 mmol/L on or after POD 3 | 17 (18%) | 7 (7.4%) | N/A |
| Zada (2007) | 369 | Serum sodium <135 mmol/L on or after POD 3 | 103 (28%) | 29 (7.9%) | N/A |
| Sata (2006) | 105 | Serum sodium <135 mmol/L on or after POD 3 | 24 (22%) | 4 (3.64%) | N/A |
| Hensen (1999) | 1571 | Serum sodium <132 mmol/L on or after POD 3 | 37 (2.4%) | 32 (2.1%) | N/A |
| Kelly (1995) | 99 | Serum sodium <135 mmol/L on or after POD 3 | 9 (9%) | 7 (7%) | N/A |
| Taylor (1995) | 2297 | Serum sodium <135 mmol/L with associated symptoms | 53 (2.3%) | 53 (2.3%) | N/A |
| Sane (1994) | 91 | Serum sodium <132 mmol/L on or after POD 3 | 32 (35%) | 18 (19.8%) | N/A |
|
